Breaking News

CVC Agrees to Acquire Mallinckrodt’s Therakos Business

Will make additional investments in the continued research, development, indication expansion and geographic expansion of Therakos.

Author Image

By: Charlie Sternberg

Associate Editor

Mallinckrodt plc, a global specialty pharmaceutical company, and CVC Capital Partners have entered into a definitive agreement under which CVC Capital Partners Fund IX will acquire the company’s Therakos business for a purchase price of $925 million, subject to customary adjustments.   Therakos is a fully integrated extracorporeal photopheresis (ECP) delivery system for autologous immunomodulatory therapy. With approvals for use in the U.S., Canada, Europe, Japan, Australia and Latin Ame...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters